Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Few studies have evaluated insulin sensitizers in comparison/association with oral contraceptives (OC) in women with polycystic ovary syndrome (PCOS) with insulin resistance (IR). This study assessed the effects of a thiazolidinedione versus an anti-androgenic estrogen-progestin followed by their sequential combinations in overweight PCOS women. METHODS AND RESULTS: Twenty-eight candidates in whom elevated insulin was not normalized after 4 months of diet were randomly assigned to 6 months of rosiglitazone 4 mg/day or to ethinyl estradiol 35 mg/cyproterone acetate 2 mg (EE/CPA: 21/28 days cycle). Each group then received both medications for another 6 months. Rosiglitazone reduced insulin, IR indices [homeostasis model assessment (HOMA) and quantitative sensitivity check index (QUICKI)] and the insulin area under the curve in response to an oral glucose tolerance test (OGTT), but had limited effect on lipids, androgens and hirsutism. EE/CPA did not modify insulin and OGTT response but increased high-density lipoprotein cholesterol and triglycerides and decreased androgens and hirsutism. Similar changes occurred during combined treatments. End results were highly significant in combined groups without noticeable side-effects or changes in safety parameters. CONCLUSIONS: In obese PCOS women with high insulin not corrected by diet, the combination of rosiglitazone and EE/CPA may be used to achieve complementary beneficial effects on endocrine-metabolic anomalies and clinical symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrasound assessment of the polycystic ovary: international consensus definitions
Balen, A. H., Laven, J. S. E., Tan, S.-L., & Dewailly, D. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg044 · Cited by 1,015
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.
Korytkowski, M. T., Mokan, M., Horwitz, M. J., & Berga, S. L. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.11.7593446 · Cited by 140 · cited 1×
“Heterogeneous results have been reported concerning the evaluation of IR in PCOS subjects taking an OC (Prelevic et al., 1990; Korytkowski et al., 1995; Escobar-Morreale et al., 2000; Morin-Papunen et al., 2000, 2003; Cagnacci et al., 2003; Harborne et al., 2003; Guido et al., 2004a; Cibula et al., 2005).”
ResultIbáñez, L., Ong, K., Ferrer, A., Amin, R., Dunger, D., & de Zegher, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022002 · Cited by 100
Sabuncu, T., Harma, M., Harma, M., Nazligul, Y., & Kilic, F. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)02162-9 · Cited by 78
Cited by
Escobar-Morreale, H. F., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., Pugeat, M., Qiao, J., Wijeyaratne, C. N., Witchel, S. F., et al. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr042 · Cited by 494
Cosma, M., Swiglo, B. A., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Elamin, M. B., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2429 · Cited by 129
“Lemay, 2006 ( 22 ) 28 women (mean age 24 yr) from India with PCOS; hirsutism not explicit eligibility criterion 16.7 17.1 4 mg rosiglitazone vs. 0.035 mg EE 2mgCPA 6”
BackgroundInfluentialFraison, E., Kostova, E., Moran, L. J., Bilal, S., Ee, C. C., Venetis, C., & Costello, M. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub3 · Cited by 94
Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management
Farshchi, H., Rane, A., Love, A., & Kennedy, R. L. (2007) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443610701667338 · Cited by 87
Hirsutism: an evidence-based treatment update
Somani, N., & Turvy, D. (2014) · American Journal of Clinical Dermatology · doi:10.1007/s40257-014-0078-4 · Cited by 69
Metadata
- Authors
- Lemay, A., Dodin, S., Turcot, L., Déchêne, F., & Forest, J.-C.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-30
- Volume
- 21
- Issue
- 1
- Pages
- 121-128
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2142177247
- Cited by
- 61
- References
- 5
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. https://app.cochat.ai/papers/10.1093/humrep/dei312
- The paper
- Lemay, A., Dodin, S., Turcot, L., Déchêne, F., & Forest, J.-C. (2006). Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Human Reproduction. https://doi.org/10.1093/humrep/dei312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.